Takeda Canada Inc. has completed the negotiations with the pan Canadian Pharmaceutical Alliance (pCPA) with a Letter of Intent (LOI) regarding TAKHZYRO (lanadelumab injection) for routine prevention of HAE attacks in adolescents and adults (12 years of age and older).
This is an important step to ensure equitable and timely access to TAKHZYRO for eligible patients across Canada. The signed LOI allows Takeda Canada to work with participating jurisdictions to implement public funding of TAKHZYRO for eligible HAE patients.
Stephen D Betschel, HBSc, MD, FRCPC, and Chair of The Canadian Hereditary Angioedema Network (CHAEN): “TAKHZYRO has the potential to transform care for patients and as a physician who treats this chronic condition, I hope to see rapid access for patients who can benefit from this important treatment option.”
Following a priority review, Health Canada authorized TAKHZYRO for routine prevention of attacks of HAE in adolescents and adults (12 years of age and older) in September 2018. In addition, Health Canada issued the Notice of Compliance (NOC) for the new presentation (300 mg/ 2 mL Prefilled Syringe) in September 2020. In November 2019, TAKHZYRO received a positive recommendation from CADTH’s Canadian Drug Expert Committee for the routine prevention of HAE attacks.
“Patients constantly live in fear of their next attack. They avoid social situations, even just going out in public, and this has a significant impact on their quality of life,” says Jacquie Badiou, President of HAE Canada: “The HAE community is thrilled with this positive step forward, because having access to a treatment option that can prevent attacks would be life-changing.”
As one of the fastest-growing pharmaceutical companies in the country, Takeda Canada is committed to delivering better health for Canadians through leading innovations in medicine.
“At Takeda, we always strive to do more for patients, and we are pleased to reach this important milestone for TAKHZYRO,” said Gamze Yüceland, General Manager, Takeda Canada Inc. “With the Letter of Intent in place, this lays the path forward for funding discussions with each of the participating jurisdictions, and we look forward to working with our partners to bring this important therapy to Canadians living with HAE as soon as possible.”